Summary
ReST Therapeutics is a French biotech company founded late 2020 that develops breakthrough therapies to treat complex central nervous system disorders, in particular, Post-Traumatic Stress Disorder (PTSD) under its various forms followed by Alzheimer Disease (AD).
Our lead candidate - FENM is a novel and proprietary chemical entity (NCE) targeting specifically a subtype of NMDA receptor (involved in synaptic plasticity) in order to facilitate stress release and neuroprotection without triggering adverse side effects of current NMDA targeting drugs. FENM will enter First-in-Human in June 2023 to initiate the clinical demonstration on PTSD.
ReST is also advancing new compounds to generate a robust library of candidates and generalize its NMDAr subtype modulation platform with the potential to treat other neurologic disorders. With the EIC support, ReST will bring FENM to clinical PoC (PhIIb) by 2027, secure a partnership with a pharma company and develop new small molecules to expand its pipeline.
Our lead candidate - FENM is a novel and proprietary chemical entity (NCE) targeting specifically a subtype of NMDA receptor (involved in synaptic plasticity) in order to facilitate stress release and neuroprotection without triggering adverse side effects of current NMDA targeting drugs. FENM will enter First-in-Human in June 2023 to initiate the clinical demonstration on PTSD.
ReST is also advancing new compounds to generate a robust library of candidates and generalize its NMDAr subtype modulation platform with the potential to treat other neurologic disorders. With the EIC support, ReST will bring FENM to clinical PoC (PhIIb) by 2027, secure a partnership with a pharma company and develop new small molecules to expand its pipeline.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101144958 |
| Start date: | 01-05-2024 |
| End date: | 30-04-2026 |
| Total budget - Public funding: | 3 558 661,25 Euro - 2 491 062,00 Euro |
Cordis data
Original description
ReST Therapeutics is a French biotech company founded late 2020 that develops breakthrough therapies to treat complex central nervous system disorders, in particular, Post-Traumatic Stress Disorder (PTSD) under its various forms followed by Alzheimer Disease (AD).Our lead candidate - FENM is a novel and proprietary chemical entity (NCE) targeting specifically a subtype of NMDA receptor (involved in synaptic plasticity) in order to facilitate stress release and neuroprotection without triggering adverse side effects of current NMDA targeting drugs. FENM will enter First-in-Human in June 2023 to initiate the clinical demonstration on PTSD.
ReST is also advancing new compounds to generate a robust library of candidates and generalize its NMDAr subtype modulation platform with the potential to treat other neurologic disorders. With the EIC support, ReST will bring FENM to clinical PoC (PhIIb) by 2027, secure a partnership with a pharma company and develop new small molecules to expand its pipeline.
Status
SIGNEDCall topic
HORIZON-EIC-2023-ACCELERATOROPEN-01Update Date
12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
